Ekkehard Schütz

TL;DR: Investigation of the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and PK values for the assessment of an individual's MPA PK parameters indicates that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of M PA PK variables that are associated with an increased rejection risk.

TL;DR: A novel, cost-effective, rapid technique was developed to quantify GcfDNA in transplant recipients and embodies a promising, potentially universal biomarker for early detection of rejection, which could enable more effective therapeutic interventions.

TL;DR: Comparing the pharmacokinetics of MPA and its major metabolite MPA glucuronide in pediatric renal transplant recipients receiving 600 mg MMF/m2 body surface area twice a day to those of adults on the currently recommended oral dose of 1 g of MMF once a day is compared.

TL;DR: Results suggest that M‐1 is the 7‐OH glucose conjugate of MPA; M‐2 is the acyl glucuronide conjugates of M PA; and M‐3 is derived from the hepatic CYP450 system.